keyword
MENU ▼
Read by QxMD icon Read
search

docetaxel outcome

keyword
https://www.readbyqxmd.com/read/29774094/selumetinib-based-therapy-in-uveal-melanoma-patient-derived-xenografts
#1
Didier Decaudin, Rania El Botty, Béré Diallo, Gerald Massonnet, Justine Fleury, Adnan Naguez, Chloé Raymondie, Emma Davies, Aaron Smith, Joanne Wilson, Colin Howes, Paul D Smith, Nathalie Cassoux, Sophie Piperno-Neumann, Sergio Roman-Roman, Fariba Némati
The prognosis of metastatic uveal melanoma (UM) is among the worst of all human cancers. The identification of near-ubiquitous GNAQ/GNA11 mutations and the activation of MAPK signaling in UM have raised hopes of more effective, targeted therapies, based on MEK inhibition, for example. We evaluated the potential of drug combinations to increase the efficacy of the MEK inhibitor selumetinib (AZD6244, ARRY-142886), in UM cell lines and Patient-Derived Xenografts. We first evaluated the combination of selumetinib and DTIC...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29768050/getting-up-to-date-in-the-management-of-soft-tissue-sarcoma
#2
Jean-Yves Blay
Surgery (+ radiation therapy in selected cases) is standard treatment for adult-type localized soft tissue sarcoma (STS). Accumulating randomized clinical evidence also supports adjuvant chemotherapy as a treatment option, although this remains contentious. Doxorubicin (± ifosfamide) is the standard first-line systemic treatment for advanced STS; however, newer chemotherapeutic agents may improve outcomes achieved with single-agent doxorubicin. In a Phase II study, adding olaratumab to doxorubicin markedly improved overall survival...
May 2018: Future Oncology
https://www.readbyqxmd.com/read/29765151/apatorsen-plus-docetaxel-versus-docetaxel-alone-in-platinum-resistant-metastatic-urothelial-carcinoma-borealis-2
#3
Jonathan E Rosenberg, Noah M Hahn, Meredith M Regan, Lillian Werner, Ajjai Alva, Saby George, Joel Picus, Robert Alter, Arjun Balar, Jean Hoffman-Censits, Petros Grivas, Richard Lauer, Elizabeth A Guancial, Christopher Hoimes, Guru Sonpavde, Constantine Albany, Mark N Stein, Tim Breen, Cindy Jacobs, Kirsten Anderson, Joaquim Bellmunt, Aly-Khan A Lalani, Sumanta Pal, Toni K Choueiri
BACKGROUND: A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy. METHODS: Multicentre, phase II study with 1:1 randomisation to apatorsen (three loading doses at 600 mg intravenous followed by weekly doses) plus docetaxel (75 mg/m2 intravenous every 21 days) (A/D) or docetaxel alone...
May 16, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29757069/accuracy-of-a-single-measurement-site-for-self-monitoring-of-patients-with-breast-cancer-at-risk-for-lymphedema
#4
Janine T Hidding, Carien H G Beurskens, Marijke T De Vries, Maria W G Nijhuis-van der Sanden, Hanneke W M van Laarhoven, Philip J van der Wees
PURPOSE: Early detection of breast cancer-related lymphedema through simple self-monitoring techniques may lead to early treatment and improved outcomes. METHODS: Prospective study of circumference measurements at four time points before, during, and after adjuvant chemotherapy with docetaxel, doxorubicin, and cyclophosphamide. Volume was calculated using the 10-cm interval circumference measurement method (reference test) and percentage difference between arms, for volume and circumference, was determined...
May 14, 2018: Physiotherapy Theory and Practice
https://www.readbyqxmd.com/read/29752180/-177-lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-lupsma-trial-a-single-centre-single-arm-phase-2-study
#5
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
BACKGROUND: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177 Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments...
May 7, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29752155/a-retrospective-study-of-treatment-for-curative-synchronous-double-primary-cancers-of-the-head-and-neck-and-the-esophagus
#6
Tabito Okamoto, Chikatoshi Katada, Shouko Komori, Keishi Yamashita, Shunsuke Miyamoto, Koichi Kano, Yutomo Seino, Hiroshi Hosono, Hiroki Matsuba, Hiromitsu Moriya, Mitsuhiro Sugawara, Mizutomo Azuma, Hiromichi Ishiyama, Satoshi Tanabe, Kazushige Hayakawa, Wasaburo Koizumi, Makito Okamoto, Taku Yamashita
OBJECTIVE: Curative synchronous double primary cancers of the head and neck and the esophagus (CSC-HE) are frequently detected, but a standard treatment remains to be established. We studied the clinical course to explore appropriate treatment strategies. METHODS: We retrospectively studied consecutive 33 patients who had CSC-HE. The disease stage was classified into 4 groups: group A, early head and neck cancer (HNC) and early esophageal cancer (EC); group B, early HNC and advanced EC; group C, advanced HNC and early EC; and group D, advanced HNC and advanced EC...
May 8, 2018: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/29748017/antiangiogenic-therapy-for-patients-with-aggressive-or-refractory-advanced-non-small-cell-lung-cancer-in-the-second-line-setting
#7
REVIEW
Martin Reck, Marina Chiara Garassino, Martina Imbimbo, Frances A Shepherd, Mark A Socinski, Jin-Yuan Shih, Anne Tsao, Pablo Lee, Katherine B Winfree, Andreas Sashegyi, Rebecca Cheng, Rocio Varea, Benjamin Levy, Edward Garon
A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapidly progresses on first-line treatment or disease that is refractory to first-line treatment, have a critical unmet medical need. These patients have a poor prognosis in the second-line setting. Several studies have recently shown that treatment with an antiangiogenic therapy may benefit these patients...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29748010/canadian-cancer-trials-group-cctg-ind211-a-randomized-trial-of-pelareorep-reolysin-in-patients-with-previously-treated-advanced-or-metastatic-non-small-cell-lung-cancer-receiving-standard-salvage-therapy
#8
Penelope A Bradbury, Donald G Morris, Garth Nicholas, Dongsheng Tu, Moustapha Tehfe, John R Goffin, Frances A Shepherd, Richard W Gregg, Jeffrey Rothenstein, Christoper Lee, Sara Kuruvilla, Bruce D Keith, Vamsee Torri, Normand Blais, Desiree Hao, Grzegorz J Korpanty, Glenwood Goss, Barbara L Melosky, Mihaela Mates, Natasha Leighl, Jean-Pierre Ayoub, Joana Sederias, Harriet Feilotter, Lesley Seymour, Scott A Laurie
OBJECTIVES: Pelareorep (reolysin), a Dearing strain of reovirus serotype 3, has demonstrated oncolytic activity as single agent and synergy with chemotherapy. We evaluated pelareorep, combined with standard second-line chemotherapy in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: This randomized phase II trial enrolled patients with advanced or metastatic NSCLC after first line chemotherapy. After a safety run-in, patients were randomized 1:1 to chemotherapy (pemetrexed [500 mg/m2, non-squamous], or docetaxel [75 mg/m2], day 1 every 21 days]) +/- pelareorep (4...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29737910/in-vitro-and-in-vivo-evaluation-of-a-novel-folate-targeted-theranostic-nanoemulsion-of-docetaxel-for-imaging-and-improved-anticancer-activity-against-ovarian-cancers
#9
Niravkumar R Patel, Aleksandr Piroyan, Srinivas Ganta, Allison B Morse, Katie M Candiloro, April L Solon, Abbegail H Nack, Corin A Galati, Collete Bora, Marisa A Maglaty, Shane W O'Brien, Samuel Litwin, Barbara Davis, Denise C Connolly, Timothy P Coleman
Ovarian cancer ranks fifth in cancer related deaths for women in USA. The high mortality rate associated with ovarian cancer is due to diagnosis at later stages of disease and the high recurrence rate of 60-80%. Recurrent ovarian cancers are more likely to present as multidrug resistance (MDR) leading to unfavorable response from 2nd and 3rd line chemotherapy. Nanoemulsions (NEs) are emerging as an attractive drug delivery system to overcome MDR challenges. NEs can also minimize exposure of therapeutic cargo to normal tissues potentially reducing side effects...
May 8, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29734647/recent-advances-in-prostate-cancer-treatment-and-drug-discovery
#10
REVIEW
Ekaterina Nevedomskaya, Simon J Baumgart, Bernard Haendler
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and apalutamide which target androgen receptor (AR) signaling, radium-223 dichloride for reduction of bone metastases, sipuleucel-T immunotherapy and taxane-based chemotherapy. Adding abiraterone acetate to androgen deprivation therapy (ADT) in order to achieve complete androgen blockade has proven highly beneficial for treatment of locally advanced prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC)...
May 4, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29731989/statin-use-and-survival-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-abiraterone-or-enzalutamide-after-docetaxel-failure-the-international-retrospective-observational-staben-study
#11
Jacob A Gordon, Carlo Buonerba, Gregory Pond, Daniel Crona, Silke Gillessen, Giuseppe Lucarelli, Sabrina Rossetti, Tanya Dorff, Salvatore Artale, Jennifer A Locke, Davide Bosso, Matthew Ivan Milowsky, Mira Sofie Witek, Michele Battaglia, Sandro Pignata, Cyrus Cherhroudi, Michael E Cox, Pietro De Placido, Dario Ribera, Aurelius Omlin, Gaetano Buonocore, Kim Chi, Christian Kollmannsberger, Daniel Khalaf, Gaetano Facchini, Guru Sonpavde, Sabino De Placido, Bernhard J Eigl, Giuseppe Di Lorenzo
Background: Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with mCRPC receiving abiraterone or enzalutamide. Materials and methods: This was a retrospective multicenter study including patients that received abiraterone or enzalutamide for mCRPC. The effect of concurrent statin use on outcomes was evaluated...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29731919/elevated-growth-differentiating-factor-15-expression-predicts-long-term-benefit-of-docetaxel-cisplatin-and-5-fluorouracil-induction-chemotherapy-in-patients-with-oral-cancer
#12
Xiao Tang, Yong-Jie Hu, Wu-Tong Ju, Yong Fu, Wen-Wen Sun, Ying Liu, Yi-Ran Tan, Li-Zhen Wang, Jiang Li, Yao-Yao Tu, Chen-Ping Zhang, Zhi-Yuan Zhang, Lai-Ping Zhong
Our previous phase 3 trial (NCT01542931) failed to demonstrate improved survival when docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy was introduced prior to surgery and postoperative radiotherapy in patients with locally advanced oral squamous cell carcinoma (OSCC). The aim of the present study was to investigate the long-term predictive value of GDF15 expression for potential personalized treatment strategies in OSCC. A total of 256 patients with stage III/IVA OSCC from our phase 3 trial were enrolled in the present study...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29731856/p16-as-a-prognostic-factor-for-the-response-to-induction-chemotherapy-in-advanced-hypopharyngeal-squamous-cell-carcinoma
#13
Joon Kyoo Lee, Kyung-Hwa Lee, Sun-Ae Kim, Sun Seog Kweon, Sang-Hee Cho, Hyun-Jeong Shim, Woo-Kyun Bae, Ik-Joo Chung, Woong-Ki Chung, Tae Mi Yoon, Sang Chul Lim, Dong Hoon Lee
The present study was conducted to investigate the prognostic significance of p16 (also known as cyclin-dependent kinase inhibitor 2A) in the treatment of induction chemoradiotherapy for advanced hypopharyngeal squamous cell carcinoma (HPSCC). Patients who were treated with at least two cycles of induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced HPSCC were reviewed in the study. The staining results were analyzed to examine the association between the chemotherapy response and the survival outcome...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29728098/the-21-gene-recurrence-score%C3%A2-assay-predicts-distant-recurrence-in-lymph-node-positive-hormone-receptor-positive-breast-cancer-patients-treated-with-adjuvant-sequential-epirubicin-and-docetaxel-based-or-epirubicin-based-chemotherapy-pacs-01-trial
#14
Frédérique Penault-Llorca, Thomas Filleron, Bernard Asselain, Frederick L Baehner, Pierre Fumoleau, Magali Lacroix-Triki, Joseph M Anderson, Carl Yoshizawa, Diana B Cherbavaz, Steven Shak, Lise Roca, Christine Sagan, Jérôme Lemonnier, Anne-Laure Martin, Henri Roché
BACKGROUND: The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+) patients treated with endocrine therapy. The purpose of this study was to evaluate the prognostic impact of RS results in N+, hormone receptor-positive (HR+) patients treated with adjuvant chemotherapy (6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel 100 mg/m2 ) plus endocrine therapy (ET) in the PACS-01 trial (J Clin Oncol 2006;24:5664-5671)...
May 4, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29722200/emergency-department-presentations-in-early-stage-breast-cancer-patients-receiving-adjuvant-and-neoadjuvant-chemotherapy
#15
Monica Tang, Patrick Horsley, Craig R Lewis
(Neo)adjuvant chemotherapy for early stage breast cancer is associated with side-effects, resulting in increased emergency department (ED) presentations. Treatment-related toxicity can affect quality of life, compromise chemotherapy delivery and treatment outcomes, and increase healthcare use. We performed a retrospective study of ED presentations in patients receiving curative chemotherapy for early breast cancer to identify factors contributing to ED presentations. Of 102 patients, 39 (38%) presented to ED within 30 days of chemotherapy, resulting in 63 ED presentations in total...
May 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29721850/exposure-response-relationship-for-ramucirumab-from-the-randomized-double-blind-phase-3-revel-trial-docetaxel-versus-docetaxel-plus-ramucirumab-in-second-line-treatment-of-metastatic-non-small-cell-lung-cancer
#16
Egbert F Smit, Edward B Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B Cohen, Ling Gao, Lisa M O'Brien, Pablo Lee, Annamaria Zimmermann, David R Ferry, Allen S Melemed, Maurice Pérol
PURPOSE: Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS: Patients received ramucirumab (10 mg/kg) or placebo plus docetaxel (75 mg/m2 ) every 3 weeks. Pharmacokinetic samples were collected. A population pharmacokinetic analysis predicted ramucirumab minimum concentration after first-dose administration (Cmin,1 ) and average concentration at steady state (Cave,ss )...
May 2, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29720224/assessing-brain-volume-changes-in-older-women-with-breast-cancer-receiving-adjuvant-chemotherapy-a-brain-magnetic-resonance-imaging-pilot-study
#17
Bihong T Chen, Sean K Sethi, Taihao Jin, Sunita K Patel, Ningrong Ye, Can-Lan Sun, Russell C Rockne, E Mark Haacke, James C Root, Andrew J Saykin, Tim A Ahles, Andrei I Holodny, Neal Prakash, Joanne Mortimer, James Waisman, Yuan Yuan, George Somlo, Daneng Li, Richard Yang, Heidi Tan, Vani Katheria, Rachel Morrison, Arti Hurria
BACKGROUND: Cognitive decline is among the most feared treatment-related outcomes of older adults with cancer. The majority of older patients with breast cancer self-report cognitive problems during and after chemotherapy. Prior neuroimaging research has been performed mostly in younger patients with cancer. The purpose of this study was to evaluate longitudinal changes in brain volumes and cognition in older women with breast cancer receiving adjuvant chemotherapy. METHODS: Women aged ≥ 60 years with stage I-III breast cancer receiving adjuvant chemotherapy and age-matched and sex-matched healthy controls were enrolled...
May 2, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29706187/locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-a-systematic-review-and-bayesian-network-meta-analysis-of-the-currently-available-treatment-options
#18
Oreste Iocca, Alessio Farcomeni, Arianna Di Rocco, Pasquale Di Maio, Paweł Golusinski, Simón Pardiñas López, Alfredo Savo, Raul Pellini, Giuseppe Spriano
BACKGROUND: There are still many unresolved questions in the management of locally advanced Head and Neck Cancer (HNC). Many chemotherapeutic drugs and radiotherapy fractionation schemes are available and not all have been evaluated in head-to-head clinical trials. This systematic review and Bayesian network meta-analysis aims to compare the available treatment strategies and chemotherapeutic options for locally advanced HNC. METHODS: We performed a search on bibliography databases, trials registries and meetings proceedings for published and unpublished randomized trials from January 1st 2000 to December 1st 2017...
May 2018: Oral Oncology
https://www.readbyqxmd.com/read/29700205/laboratory-based-biomarkers-and-liver-metastases-in-metastatic-castration-resistant-prostate-cancer
#19
Patrick M Cotogno, Lahiru K Ranasinghe, Elisa M Ledet, Brian E Lewis, Oliver Sartor
BACKGROUND: Metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases have a poor prognosis. No large studies have investigated the clinical and biochemical parameters associated with liver metastases in this population. MATERIALS AND METHODS: Patient data made available via Project Data Sphere were collected from 1,281 men with mCRPC who were enrolled on to three phase III clinical trials for the treatment of their disease. Multiple logistic regression was performed on eight clinical and biochemical baseline variables to test their association with the presence of liver metastases on baseline radiographic imaging...
April 26, 2018: Oncologist
https://www.readbyqxmd.com/read/29695917/four-cycles-of-adriamycin-and-cyclophosphamide-followed-by-four-cycles-of-docetaxel-nsabp-b27-with-concomitant-trastuzumab-as-neoadjuvant-therapy-for-high-risk-early-stage-her2-positive-breast-cancer-patients
#20
Hikmat Abdel-Razeq, Salwa S Saadeh, Mahmoud Abu-Nasser, Hazem Abdulelah, Lina Marie, Murad Salam, Basel Al-Haj Ali, Mohammad Ibrahim, Dalia Rimawi
Background: The majority of breast cancer patients in Jordan are diagnosed at a young age and present with metastatic or locally advanced disease. The National Surgical Adjuvant Breast and Bowel Project Protocol B27 (NSABP-B27) (four cycles of adriamycin and cyclophosphamide [AC] followed by four cycles of docetaxel) is a standard neoadjuvant regimen in our institution. In this study, we report the efficacy of adding trastuzumab to docetaxel in this regimen for high-risk human epidermal growth factor receptor 2 (HER2)-positive early-stage disease...
2018: OncoTargets and Therapy
keyword
keyword
58392
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"